ClinicalTrials.gg
CompletedNCT00614523Updated Nov 7, 2022Results posted

Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

A Phase 2 interventional study of Placebo and Romiplostim in MDS, Myelodysplastic Syndromes and Thrombocytopenia, sponsored by Amgen. Completed. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2022-11-07.

Sponsored by Amgen · Phase 2, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies in Myelodysplastic Syndromes by Amgen — none open to participants now, none under way, none of them phase 3. Myelodysplastic Syndromes · Amgen.

Enrollment
Largest of 11
250 · median 72
Started
2008
the only one that year
Phase 2
5 of 11
none open now
Registered
6th of 11
by date

Among the 11 studies in Myelodysplastic Syndromes by Amgen, this one has the largest enrollment, is the only one that started in 2008, is one of 5 in phase 2, and was the 6th registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

None of the 11 studies in Myelodysplastic Syndromes by Amgen is open now. The open studies under Myelodysplastic Syndromes, anywhere →

Who these studies take

Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Myelodysplastic Syndromes by Amgen as a file.
02

Study summary

The Data Monitoring Committee (DMC) for study 20060198 recommended that all subjects discontinue treatment of study drug and continue to be followed for long term follow-up. Amgen adopted the DMC recommendation.

Read the detailed description

This is a Phase 2, multicenter, randomized, double blind, placebo controlled study designed to assess the efficacy and safety of romiplostim (formerly, AMG 531) treatment in thrombocytopenic MDS patients. The study is composed of a 26-week placebo controlled test treatment period (romiplostim versus Placebo), a 4 week interim wash-out period, a 24-week placebo controlled extended treatment period, and a 4-week follow-up period followed by an End of Study (EOS) visit. During the interim wash-out period, a bone marrow biopsy will be performed in the absence of growth factor to assess changes in the marrow. In the extended treatment period, safety assessments will continue and participants will be allowed to receive any standard of care treatments for MDS. Patients will be followed for survival for an additional 60 months following the End of Study (EOS) visit.

03

Conditions studied

  • MDS
  • Myelodysplastic Syndromes
  • Thrombocytopenia

Keywords

  • MDS
  • Low Risk MDS
  • Intermediate-1 Risk MDS
  • Thrombocytopenia
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: • Diagnosis of MDS using the World Health Organization (WHO) classification for myeloid neoplasms as assessed during the screening period. • Per MDS International Prognostic Scoring System (IPSS), low or intermediate-1 risk MDS as assessed during the screening period. • Mean of the 2 counts taken within 4 weeks prior to randomization must be: - ≤ 20 x 10\^9/L, (with no individual count >30 x 10\^9/L during the screening period), with or without history of bleeding associated with diagnosis of MDS, OR - ≤ 50 x 10\^9/L, (with no individual count >60 x 10\^9/L during the screening period) with a history of bleeding associated with the diagnosis of MDS. • Patients must be ≥18 and ≤ 90 years of age at time of . Patients between 85 and 90 years of age must have been diagnosed with MDS ≤ 5 years from study start. • (ECOG) performance status of 0-2. • Adequate liver function, as evidenced by (ALT) ≤ 3 times laboratory normal range, aspartate aminotransferase (AST) ≤ 3 times laboratory normal range and total ≤ 2.0 times laboratory normal range. (Adequate liver function for patients with confirmed diagnosis of Gilbert's Disease evidenced by ALT ≤ 3 times laboratory normal range, and AST ≤ 3 times laboratory normal range.) • Serum creatinine concentration ≤ 2 mg/dl (≤176.8 μmol/L). • Bone marrow and aspirate with cytogenetics within 3 months of starting first dose of product. • Written Informed Consent. Exclusion Criteria: • Have ever received any disease-modifying treatment for MDS. • Previously diagnosed with intermediate-2 or high risk MDS using the IPSS. • Prior history of leukemia, aplastic anemia, or other non-MDS related bone marrow stem cell disorder. • Prior history of hematopoietic stem cell transplantation. • Persistent peripheral blood monocytosis (≥ 3 months with an absolute monocyte count >1,000/μL) or known diagnosis of Chronic Myelomonocytic Leukemia per French-American-British Classification System for MDS (FAB) criteria. • Prior (other than in situ cervical cancer, non-melanoma skin cancer, or in situ carcinoma) unless treated with curative intent and without evidence of disease for ≥ 3 years before randomization. • Active or uncontrolled infections. • Unstable angina, congestive heart failure ( [NYHA] > class II), uncontrolled hypertension (diastolic >100 mmHg), uncontrolled cardiac arrhythmia, or recent (within 1 year) myocardial infarction. • History of arterial thrombosis (eg, stroke or ) within the past year. • History of venous thrombosis that currently requires anti-coagulation therapy. • Received Interleukin (IL)-11 within 4 weeks of first dose of investigational product. • Have previously received any thrombopoietic growth factor. • Receipt of granulocyte-colony stimulating factor, (G-CSF), pegylated-G-CSF, or granulocyte macrophage-colony stimulating factor (GM-CSF) within 4 weeks of first dose of investigational product. • Planned receipt of peg-G-CSF or GM-CSF after first dose of investigational product. • Pregnant or breast feeding. • Patients of who are not using adequate precautions, in the judgment of the investigator. Amgen recommends double barrier contraception is used for all applicable patients enrolled on this study. A double barrier method is defined as two methods of contraception, for example 2 actual barrier methods, or one actual barrier method and one hormonal method. • Patient has known sensitivity to any recombinant E coli-derived product (eg, Infergen®, Neupogen®, Somatropin, and Actimmune). • Previously enrolled into the 20060198 study or another romiplostim study. • Inability to comply with study procedures. • Patient currently is enrolled in or has not yet completed at least 30 days since ending other investigational device or drug study.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
250 participants (actual)

Study arms

  • Experimental
    Romiplostim

    Weekly subcutaneous dosing based on platelet count for 26 weeks during the Test Treatment Period and for 24 weeks during the Extended Treatment Period, separated by a 4-week interim washout period. Starting dose is at 750 μg, up to a maximum dose of 1000 μg, or reduced to a minimum of 250 μg.

    Biological: Romiplostim

  • Placebo comparator
    Placebo

    Weekly subcutaneous dosing with blinded matching placebo dose level for 26 weeks during the Test Treatment Period and for 24 weeks during the Extended Treatment Period, separated by a 4-week interim washout period.

    Drug: Placebo

Interventions

  • DrugPlacebo

    Placebo is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.

  • BiologicalRomiplostim

    Romiplostim is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.

06

What researchers measure

Primary outcomes

  1. Number of Clinically Significant Bleeding Events

    A clinically significant bleeding event is defined as any bleeding event of grade ≥ 2 per the modified World Health Organization (WHO) bleeding scale: • Grade 0 = no bleeding • Grade 1 = petechia or mucosal or retinal bleeding not requiring intervention • Grade 2 = melena, hematemesis, hematuria, hemoptysis • Grade 3 = bleeding required red cell transfusion • Grade 4 = retinal bleeding with visual impairment • Grade 5 = non-fatal cerebral bleeding • Grade 6 = fatal cerebral bleeding • Grade 7 = fatal non-cerebral bleeding. Bleeding events that continue for more than 7 days were counted as separate events every eighth day. Multiple events that arose from one organ system on one day were collapsed into one single event. Bleeding events with a start date between the first dose date and the last dose date of the test treatment period+7 days are included.

    Time frame: Test Treatment Period (Weeks 1-26)

Secondary outcomes

  1. Annualized Rate of Platelet Transfusion Events

    A discrete platelet transfusion is any number of platelet transfusion administered within a 3-day period. Transfusions administered more than 3 days apart are counted as separate events. Transfusion given in the absence of any bleeding, when platelet count is \>10x10\^9/L, is not counted as a platelet transfusion event. Events with start date between the first dose date and the last dose date of the test treatment period +7 days are included. Exposure adjusted event rate per 100 patient-years = (events / patient-years \* 100). Patient Year = total patient years of exposure to investigational product during 26 weeks test treatment period.

    Time frame: Test Treatment Period (Weeks 1-26)

  2. Annualized Rate of Overall Bleeding Events

    The time from first dose of study drug to the last dose of 26-week test treatment period. A bleeding event is defined as any bleeding event reported during the test treatment period. Bleeding events that continue for more than 7 days are counted as separate events every eighth day. Multiple events that arose from one organ system on one day are collapsed into one single event. Exposure adjusted event rate per 100 patient-years = events / patient-year \* 100).

    Time frame: Test Treatment Period (Weeks 1-26)

  3. Annualized Rate of Total Platelet Transfusion Units

    The time from first dose of study drug to the last dose of 26-week test treatment period. A unit of platelets is defined as a single pack of pooled platelet-rich plasma comprised of 6 to 8 individual platelet concentrate packs (200 to 400 mL), a single pack of pooled buffy-coat concentrate, or 1 apheresis (single donor) concentrate. Exposure adjusted event rate per 100 patient-years = events / patient-years \* 100.

    Time frame: Test Treatment Period (Weeks 1-26)

  4. Number of Participants With Platelet Hematologic Improvement (HI-P)

    Platelet Hematologic Improvemen defined by the international working group (IWG) as: an absolute increase in platelet count of ≥ 30 x 10\^9/L for a patient starting with a platelet count of ≥ 20 x 10\^9/L or an increase in platelet count from \< 20 x 10\^9/L to ≥ 20 x 10\^9/L and by at least 100% in a patient that started with a platelet count \< 20 x 10\^9/L. To account for any possible contribution from platelet transfusions, platelet counts within 3 days following administration of platelet transfusion is not counted towards the platelet hematologic improvement endpoint. If no platelet measurements are available on the weekly scheduled dose day, then that week is not counted towards the platelet hematologic improvement endpoint.

    Time frame: Test Treatment Period (Weeks 1-26)

  5. Exposure-adjusted Total Duration of Platelet Hematologic Improvement (HI-P) in the Absence of Platelet Transfusions

    Duration for participants who did not report HI-P during the period is 0. A platelet hematologic improvement (HI-P) is defined by an MDS International Working criteria as patients with a baseline platelet count of ≥ 20 x 10\^9/L achieving an absolute increase of ≥ 30 x 10\^9/L or increasing the platelet count to above 20 x 10\^9/L and by at least 100% in patients with a baseline of \< 20 x 10\^9/L for at least 8 consecutive weeks. To account for any possible contribution from platelet transfusions, platelet counts within 3 days following administration of platelet transfusion is not counted towards the platelet hematologic improvement endpoint. If no platelet measurements are available on the weekly scheduled dose day, then that week is not counted towards the platelet hematologic improvement endpoint. The durations of HI-P are cumulative if more than one incidence occurred. Exposure adjusted event rate per 100 patient-weeks = total number of weeks / patient-weeks \* 100.

    Time frame: Test Treatment Period (Weeks 1-26)

  6. Number of Participants Who Died

    Time frame: From randomization to 58 weeks, the end of study visit or the closest available follow-up information up to 58 weeks from the long term follow-up for those who discontinued the study early, with a data cut-off date of 20 July 2012.

  7. Time to Death

    Overall survival was calculated using Kaplan-Meier methods. For patients who discontinued early, additional information from the long term follow-up are added (closest available follow-up information up to 58 weeks).

    Time frame: From randomization to 58 weeks, the end of study visit or the closest available follow-up information up to 58 weeks from the long term follow-up for those who discontinued the study early, with a data cut-off date of 20 July 2012.

  8. Kaplan-Meier Estimate of Survival at Month 12

    Overall survival was calculated using Kaplan-Meier methods.

    Time frame: Month 12, with a data cut-off date of 20 July 2012.

  9. Annualized Rate of Patient-reported Bleeding Events

    The number of bleeding events was obtained from the thrombocytopenia symptoms (Th-symptoms) survey. Patients reported spontaneous bleeding to have occurred 0, 1 or 2, 3 or 4, 5 or 6, or 7 or more times in the past week. The lower threshold of bleeding counts is used for conservative purposes (i.e., the "3" is used for the response option of "3 or 4 times"). Exposure adjusted event rate per 100 patient-years = number of events / patient-year \* 100.

    Time frame: Test Treatment Period (Weeks 1-26)

07

Results

Posted Aug 13, 2013

Participant flow

First Subject Enrolled: 21 July 2008, Last Subject Enrolled: 16 December 2010.

Participant flow — Overall Study
MilestonePlaceboRomiplostim
Started83167
Completed2036
Not completed63131
Withdrew: Adverse event420
Withdrew: Death58
Withdrew: Lack of efficacy911
Withdrew: Lost to follow-up01
Withdrew: Protocol violation32
Withdrew: Withdrawal by subject1222
Withdrew: Other611
Withdrew: Ineligibility determined12
Withdrew: Disease progression08
Withdrew: Administrative decision2346

Outcome measures

PrimaryNumber of Clinically Significant Bleeding Events

A clinically significant bleeding event is defined as any bleeding event of grade ≥ 2 per the modified World Health Organization (WHO) bleeding scale: • Grade 0 = no bleeding • Grade 1 = petechia or mucosal or retinal bleeding not requiring intervention • Grade 2 = melena, hematemesis, hematuria, hemoptysis • Grade 3 = bleeding required red cell transfusion • Grade 4 = retinal bleeding with visual impairment • Grade 5 = non-fatal cerebral bleeding • Grade 6 = fatal cerebral bleeding • Grade 7 = fatal non-cerebral bleeding. Bleeding events that continue for more than 7 days were counted as separate events every eighth day. Multiple events that arose from one organ system on one day were collapsed into one single event. Bleeding events with a start date between the first dose date and the last dose date of the test treatment period+7 days are included.

Time frame:
Test Treatment Period (Weeks 1-26)
Reported as:
Number · events
Number of Clinically Significant Bleeding Events
eventsPlaceboRomiplostim
Number of Clinically Significant Bleeding Events116178
Statistical analysis
  • Placebo vs Romiplostim · Anderson-Gill model · p = 0.13 · Hazard ratio (hr): 0.83 · 95% CI 0.66 to 1.05Romiplostim /Placebo
SecondaryAnnualized Rate of Platelet Transfusion Events

A discrete platelet transfusion is any number of platelet transfusion administered within a 3-day period. Transfusions administered more than 3 days apart are counted as separate events. Transfusion given in the absence of any bleeding, when platelet count is \>10x10\^9/L, is not counted as a platelet transfusion event. Events with start date between the first dose date and the last dose date of the test treatment period +7 days are included. Exposure adjusted event rate per 100 patient-years = (events / patient-years \* 100). Patient Year = total patient years of exposure to investigational product during 26 weeks test treatment period.

Time frame:
Test Treatment Period (Weeks 1-26)
Reported as:
Mean · events per 100 patient-years
Annualized Rate of Platelet Transfusion Events
events per 100 patient-yearsPlaceboRomiplostim
Annualized Rate of Platelet Transfusion Events1013.5 (905.2 to 1131.3)748.9 (681.3 to 821.4)
Statistical analysis
  • Placebo vs Romiplostim · Poisson regression model · p = <0.001 · Risk ratio (rr): 0.766 · 95% CI 0.66 to 0.88Romiplostim /Placebo
SecondaryAnnualized Rate of Overall Bleeding Events

The time from first dose of study drug to the last dose of 26-week test treatment period. A bleeding event is defined as any bleeding event reported during the test treatment period. Bleeding events that continue for more than 7 days are counted as separate events every eighth day. Multiple events that arose from one organ system on one day are collapsed into one single event. Exposure adjusted event rate per 100 patient-years = events / patient-year \* 100).

Time frame:
Test Treatment Period (Weeks 1-26)
Reported as:
Mean · events per 100 patient-years
Annualized Rate of Overall Bleeding Events
events per 100 patient-yearsPlaceboRomiplostim
Annualized Rate of Overall Bleeding Events3786.4 (3574.1 to 4008.0)3459.9 (3312.8 to 3611.9)
Statistical analysis
  • Placebo vs Romiplostim · Poisson regression model · p = 0.026 · Risk ratio (rr): 0.922 · 95% CI 0.86 to 0.99Romiplostim /Placebo
SecondaryAnnualized Rate of Total Platelet Transfusion Units

The time from first dose of study drug to the last dose of 26-week test treatment period. A unit of platelets is defined as a single pack of pooled platelet-rich plasma comprised of 6 to 8 individual platelet concentrate packs (200 to 400 mL), a single pack of pooled buffy-coat concentrate, or 1 apheresis (single donor) concentrate. Exposure adjusted event rate per 100 patient-years = events / patient-years \* 100.

Time frame:
Test Treatment Period (Weeks 1-26)
Reported as:
Mean · units per 100 patient-years
Annualized Rate of Total Platelet Transfusion Units
units per 100 patient-yearsPlaceboRomiplostim
Annualized Rate of Total Platelet Transfusion Units3120.2 (2927.8 to 3322.0)2221.8 (2104.2 to 2344.2)
Statistical analysis
  • Placebo vs Romiplostim · Poisson Regression model · p = <0.001 · Risk ratio (rr): 0.739 · 95% CI 0.68 to 0.8Romiplostim /Placebo
SecondaryNumber of Participants With Platelet Hematologic Improvement (HI-P)

Platelet Hematologic Improvemen defined by the international working group (IWG) as: an absolute increase in platelet count of ≥ 30 x 10\^9/L for a patient starting with a platelet count of ≥ 20 x 10\^9/L or an increase in platelet count from \< 20 x 10\^9/L to ≥ 20 x 10\^9/L and by at least 100% in a patient that started with a platelet count \< 20 x 10\^9/L. To account for any possible contribution from platelet transfusions, platelet counts within 3 days following administration of platelet transfusion is not counted towards the platelet hematologic improvement endpoint. If no platelet measurements are available on the weekly scheduled dose day, then that week is not counted towards the platelet hematologic improvement endpoint.

Time frame:
Test Treatment Period (Weeks 1-26)
Reported as:
Number · Participants
Number of Participants With Platelet Hematologic Improvement (HI-P)
ParticipantsPlaceboRomiplostim
Number of Participants With Platelet Hematologic Improvement (HI-P)361
Statistical analysis
  • Placebo vs Romiplostim · Cochran-Mantel-Haenszel · p = <0.001 · Odds ratio (or): 15.6 · 95% CI 4.7 to 51.8Romiplostim /Placebo
SecondaryExposure-adjusted Total Duration of Platelet Hematologic Improvement (HI-P) in the Absence of Platelet Transfusions

Duration for participants who did not report HI-P during the period is 0. A platelet hematologic improvement (HI-P) is defined by an MDS International Working criteria as patients with a baseline platelet count of ≥ 20 x 10\^9/L achieving an absolute increase of ≥ 30 x 10\^9/L or increasing the platelet count to above 20 x 10\^9/L and by at least 100% in patients with a baseline of \< 20 x 10\^9/L for at least 8 consecutive weeks. To account for any possible contribution from platelet transfusions, platelet counts within 3 days following administration of platelet transfusion is not counted towards the platelet hematologic improvement endpoint. If no platelet measurements are available on the weekly scheduled dose day, then that week is not counted towards the platelet hematologic improvement endpoint. The durations of HI-P are cumulative if more than one incidence occurred. Exposure adjusted event rate per 100 patient-weeks = total number of weeks / patient-weeks \* 100.

Time frame:
Test Treatment Period (Weeks 1-26)
Reported as:
Mean · weeks per 100 patient-weeks
Exposure-adjusted Total Duration of Platelet Hematologic Improvement (HI-P) in the Absence of Platelet Transfusions
weeks per 100 patient-weeksPlaceboRomiplostim
Exposure-adjusted Total Duration of Platelet Hematologic Improvement (HI-P) in the Absence of Platelet Transfusions2.57 (1.85 to 3.47)35.02 (32.98 to 37.16)
Statistical analysis
  • Placebo vs Romiplostim · Poisson regression model · p = 0.032 · Risk ratio (rr): 1.402 · 95% CI 1.03 to 1.91Romiplostim /Placebo
SecondaryNumber of Participants Who Died
Time frame:
From randomization to 58 weeks, the end of study visit or the closest available follow-up information up to 58 weeks from the long term follow-up for those who discontinued the study early, with a data cut-off date of 20 July 2012.
Reported as:
Number · participants
Number of Participants Who Died
participantsPlaceboRomiplostim
Number of Participants Who Died17 (NA to NA)30 (NA to NA)
SecondaryTime to Death

Overall survival was calculated using Kaplan-Meier methods. For patients who discontinued early, additional information from the long term follow-up are added (closest available follow-up information up to 58 weeks).

Time frame:
From randomization to 58 weeks, the end of study visit or the closest available follow-up information up to 58 weeks from the long term follow-up for those who discontinued the study early, with a data cut-off date of 20 July 2012.
Reported as:
Median · months
Time to Death
monthsPlaceboRomiplostim
Time to DeathNA (NA to NA)NA (NA to NA)
SecondaryKaplan-Meier Estimate of Survival at Month 12

Overall survival was calculated using Kaplan-Meier methods.

Time frame:
Month 12, with a data cut-off date of 20 July 2012.
Reported as:
Number · percentage of participants
Kaplan-Meier Estimate of Survival at Month 12
percentage of participantsPlaceboRomiplostim
Kaplan-Meier Estimate of Survival at Month 1278 (67 to 86)83 (76 to 88)
SecondaryAnnualized Rate of Patient-reported Bleeding Events

The number of bleeding events was obtained from the thrombocytopenia symptoms (Th-symptoms) survey. Patients reported spontaneous bleeding to have occurred 0, 1 or 2, 3 or 4, 5 or 6, or 7 or more times in the past week. The lower threshold of bleeding counts is used for conservative purposes (i.e., the "3" is used for the response option of "3 or 4 times"). Exposure adjusted event rate per 100 patient-years = number of events / patient-year \* 100.

Time frame:
Test Treatment Period (Weeks 1-26)
Reported as:
Mean · events per 100 patient-years
Annualized Rate of Patient-reported Bleeding Events
events per 100 patient-yearsPlaceboRomiplostim
Annualized Rate of Patient-reported Bleeding Events1995 (1840.5 to 2158.9)1264 (1175.1 to 1357.7)
Statistical analysis
  • Placebo vs Romiplostim · Poisson regression model · p = <0.001 · Risk ratio (rr): 0.639 · 95% CI 0.57 to 0.71Romiplostim /Placebo

Adverse events

Collected over 58 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—22/82 (26.8%)74/82 (90.2%)
Romiplostim—67/168 (39.9%)146/168 (86.9%)
Most frequent serious events
Showing 10 of 106
Most frequent serious events
EventPlaceboRomiplostim
PneumoniaInfections and infestations0/828/168
AnaemiaBlood and lymphatic system disorders2/827/168
PyrexiaGeneral disorders1/827/168
ThrombocytopeniaBlood and lymphatic system disorders0/826/168
Atrial fibrillationCardiac disorders1/825/168
Febrile neutropeniaBlood and lymphatic system disorders2/822/168
DiarrhoeaGastrointestinal disorders2/821/168
Cerebral haemorrhageNervous system disorders2/820/168
DyspnoeaRespiratory, thoracic and mediastinal disorders2/821/168
Head injuryInjury, poisoning and procedural complications0/824/168
Most frequent other events
Showing 10 of 42
Most frequent other events
EventPlaceboRomiplostim
HaematomaVascular disorders33/8258/168
EpistaxisRespiratory, thoracic and mediastinal disorders32/8266/168
PetechiaeSkin and subcutaneous tissue disorders20/8242/168
ContusionInjury, poisoning and procedural complications10/8241/168
Gingival bleedingGastrointestinal disorders14/8233/168
HaemorrhageVascular disorders15/8224/168
HeadacheNervous system disorders10/8229/168
NauseaGastrointestinal disorders7/8227/168
Oedema peripheralGeneral disorders7/8226/168
CoughRespiratory, thoracic and mediastinal disorders10/8225/168

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboRomiplostimTotal
Mean67 ± 11.568.4 ± 1267.9 ± 11.8
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboRomiplostimTotal
Female3072102
Male5395148
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboRomiplostimTotal
White or Caucasian79156235
Black or African American011
Hispanic or Latino145
Asian112
Other257
Myelodysplastic Syndromes World Health Organization Classification
Myelodysplastic Syndromes World Health Organization Classification(Participants)PlaceboRomiplostimTotal
RA5611
RARS022
RAEB-192433
RAEB-2011
RCMD55114169
RCMD-RS246
MDS-U121628
MDS associated with isolated del 5Q000
Prior MDS Therapy
Prior MDS Therapy(Participants)PlaceboRomiplostimTotal
No70133203
Yes133447
Baseline Platelet Counts
Baseline Platelet Counts(10^9/L)PlaceboRomiplostimTotal
Mean21.5 ± 1322.3 ± 11.522.0 ± 12.0
International Prognostic Scoring System (IPSS) Total Score
International Prognostic Scoring System (IPSS) Total Score(Participants)PlaceboRomiplostimTotal
0234063
0.53886124
1203454
1.5011
Missing268
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Diao G, Zeng D, Hu K, Ibrahim JG. Modeling event count data in the presence of informative dropout with application to bleeding and transfusion events in myelodysplastic syndrome. Stat Med. 2017 Sep 30;36(22):3475-3494. doi: 10.1002/sim.7351. Epub 2017 May 30. PubMed 28560768 ↗
  • Kantarjian HM, Fenaux P, Sekeres MA, Szer J, Platzbecker U, Kuendgen A, Gaidano G, Wiktor-Jedrzejczak W, Carpenter N, Mehta B, Franklin J, Giagounidis A. Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial. Lancet Haematol. 2018 Mar;5(3):e117-e126. doi: 10.1016/S2352-3026(18)30016-4. Epub 2018 Jan 26. PubMed 29396092 ↗
  • Giagounidis A, Mufti GJ, Fenaux P, Sekeres MA, Szer J, Platzbecker U, Kuendgen A, Gaidano G, Wiktor-Jedrzejczak W, Hu K, Woodard P, Yang AS, Kantarjian HM. Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia. Cancer. 2014 Jun 15;120(12):1838-46. doi: 10.1002/cncr.28663. Epub 2014 Apr 4. PubMed 24706489 ↗
  • Platzbecker U, Sekeres MA, Kantarjian H, Giagounidis A, Mufti GJ, Jia C, Yang AS, Fenaux P. Relationship of different platelet response criteria and patient outcomes in a romiplostim myelodysplastic syndromes trial. Leukemia. 2014 Dec;28(12):2418-21. doi: 10.1038/leu.2014.253. Epub 2014 Sep 2. No abstract available. PubMed 25179731 ↗
  • Sekeres MA, Giagounidis A, Kantarjian H, Mufti GJ, Fenaux P, Jia C, Yang AS, Platzbecker U. Development and validation of a model to predict platelet response to romiplostim in patients with lower-risk myelodysplastic syndromes. Br J Haematol. 2014 Nov;167(3):337-45. doi: 10.1111/bjh.13037. Epub 2014 Jul 14. PubMed 25039607 ↗
  • Diao G, Zeng D, Hu K, Ibrahim JG. Semiparametric frailty models for zero-inflated event count data in the presence of informative dropout. Biometrics. 2019 Dec;75(4):1168-1178. doi: 10.1111/biom.13085. Epub 2019 Sep 2. PubMed 31106400 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2008 to primary completion in Mar 2011, 32 months.

Results were first posted in Aug 2013, 2 years 4 months after primary completion.

Of 52 industry-sponsored phase 2 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 62. This study's 32 months is below that.

Counting every sponsor, half of 279 studies reached it within 66 months; a quarter within 40 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2008
First posted
Feb 13, 2008
StartActual
Jul 21, 2008
Primary completionActual
Mar 31, 2011
CompletionActual
Nov 30, 2015
Results first posted
Aug 13, 2013
Last update
Nov 7, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 7, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00614523
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Feb 13, 2008
Start date
Jul 21, 2008
Primary completion
Mar 31, 2011
Completion
Nov 30, 2015
Results posted
Aug 13, 2013
Last update
Nov 7, 2022

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Romiplostim

Start the discussion